BC Extra | Nov 1, 2019
Company News

Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

Recently launched psoriasis drug Skyrizi exceeded sales expectations for the second quarter in a row, as immunology and hemato-oncology drugs continue to drive AbbVie’s growth ahead of anticipated U.S. biosimilar competition for Humira. Sales of...
BC Extra | Aug 29, 2019
Company News

With Rova-T killed, spotlight shifts to AbbVie’s hematology, immunology franchises

The final clinical failure of a program AbbVie once regarded as the "anchor asset" in its solid tumor portfolio leaves AbbVie with little or nothing to show for its acquisition of Stemcentrx in 2016 for...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BC Week In Review | Jan 11, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Jan. 4 it...
BC Extra | Jan 6, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will...
BC Week In Review | Dec 7, 2018
Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
BC Extra | Dec 5, 2018
Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product...
BioCentury | Aug 10, 2018
Finance

Wnt to market

With no traditional life science VCs in its syndicate and little publicly disclosed about its science, Samumed LLC was able to raise a $438 million round at a premoney valuation of $12 billion, bringing its...
Regulatory | Apr 20, 2018
Regulatory

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
BC Extra | Apr 18, 2018
Company News

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
Items per page:
1 - 10 of 27